<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593121</url>
  </required_header>
  <id_info>
    <org_study_id>271HV101</org_study_id>
    <nct_id>NCT04593121</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the safety and tolerability of single and multiple&#xD;
      ascending subcutaneous (SC) doses and single ascending intravenous (IV) doses of BIIB107 in&#xD;
      healthy adult participants. The secondary objectives are to characterize the single-dose&#xD;
      pharmacokinetic (PK) of SC and IV BIIB107 in healthy adult participants and to characterize&#xD;
      the multiple-dose PK of SC BIIB107 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIIB107 is a monoclonal antibody that targets alpha-4 integrins and is currently in&#xD;
      development for people with multiple sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs): Single Ascending Dose (SAD)</measure>
    <time_frame>Day -1 up to Day 84</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs): Multiple Ascending Dose (MAD)</measure>
    <time_frame>Day -1 up to Day 117</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUCinf): SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax): SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax): SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2): SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL) for IV Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of SC Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution During the Terminal Phase (Vss) for IV Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) for SC Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavaibility of SC Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption Rate Profile of SC Doses: SAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t1/2): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (R): MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of SC Doses: MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) for SC Doses: MAD</measure>
    <time_frame>Day 1 pre-dose and multiple time-points up to Day 117</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 2 of BIIB107 or placebo intravenous (IV) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Dose 5 of BIIB107 or placebo IV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB107</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_label>Cohort 5A</arm_group_label>
    <arm_group_label>Cohort 6A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_label>Cohort 5A</arm_group_label>
    <arm_group_label>Cohort 6A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must have a body mass index (BMI) between 18 and 30 kilogram per meter square&#xD;
             (kg/m^2), inclusive, and must weigh at least 55 kilogram (kg)&#xD;
&#xD;
          -  All women of childbearing potential must practice highly effective contraception&#xD;
             during the study and for a period of 90 days, which is expected to be more than 5&#xD;
             times the half-life of BIIB107 treatment. Men must practice effective contraception&#xD;
             during the study and for a period of 5 times the half-life of BIIB107 or 90 days after&#xD;
             their last dose of study treatment. In addition, participants should not donate sperm&#xD;
             or eggs during the study and for at least 5 times the half-life of BIIB107 or 90 days&#xD;
             after their last dose of study treatment&#xD;
&#xD;
          -  Negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain&#xD;
             reaction (PCR) test at Screening and check-in/admission.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of or positive test result at Screening for human immunodeficiency virus&#xD;
             (HIV-1/HIV-2) antibodies&#xD;
&#xD;
          -  Positive test result at Screening for hepatitis C virus (HCV) antibody (Ab).&#xD;
&#xD;
          -  Current hepatitis B infection (defined as per protocol).&#xD;
&#xD;
          -  Signs of active herpes simplex type 1 and 2 or varicella within 4 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Evidence of current SARS-CoV-2 infection within 4 weeks prior to Screening, at&#xD;
             Screening, between Screening and in-patient admission (Day -1), or at admission (Day&#xD;
             -1), including but not limited to a fever (temperature &gt;37.5°C), new and persistent&#xD;
             cough, breathlessness, or loss of taste or smell, as per the judgement of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Close contact with an individual with coronavirus disease 2019 (COVID-19) infection&#xD;
             within 14 days prior to admission (Day -1). Close contact is defined as being within 6&#xD;
             feet of an infected person as confirmed via laboratory assessment for at least 15&#xD;
             minutes within 2 days of symptom onset (or within 2 days of specimen collection for&#xD;
             COVID-19 testing for close contact with asymptomatic person).&#xD;
&#xD;
          -  History of tuberculosis (TB) or positive QuantiFERON® TB Gold test or, if the&#xD;
             QuantiFERON TB Gold test is not available, a positive purified protein derivative&#xD;
             (PPD/Mantoux test; positive PPD/Mantoux test is defined as ≥5 millimeter (mm) of&#xD;
             induration [size of raised lump, not redness])&#xD;
&#xD;
          -  John Cunningham virus (JCV) seropositivity at Screening (for potential participants&#xD;
             enrolling in the MAD part)&#xD;
&#xD;
          -  Ongoing or past malignancy, carcinoma in situ, or high-grade dysplasia (with the&#xD;
             exception of no more than 1 basal cell carcinoma or squamous cell carcinoma that was&#xD;
             completely excised and cured at least 12 months prior to randomization)&#xD;
&#xD;
          -  Any prior exposure to the following immunomodulator therapies per investigator&#xD;
             judgement: natalizumab or any other anti-α4 integrin antibody, anti-CD20,&#xD;
             sphingosine-1-phosphate receptor modulators, or fumarate therapies.&#xD;
&#xD;
          -  Any previous exposure to immunosuppressants (in particular mitoxantrone, methotrexate,&#xD;
             azathioprine, cyclophosphamide, and mycophenolate mofetil). Prior exposure to other&#xD;
             immunosuppressants not captured here should be discussed with Sponsor prior to&#xD;
             enrollment.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

